Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Judith Kaiser

3PUBLICATIONS

35CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Nov 22, 2024

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.

Randy F Sweis, Gurkamal S Chatta, Rohit K Jain

|Oct 02, 2024

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Kathryn Lurain, Ramya Ramaswami, Irene Ekwede

|Jun 11, 2021

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Katelyn T Byrne, Courtney B Betts, Rosemarie Mick

Pageof 1

Frequent Collaborators

2 joint publications

Elad Sharon

2 joint publications

Steven P Fling

1 joint publications

David L Bajor

1 joint publications

Daniel A Laheru

1 joint publications

E Gabriela Chiorean

1 joint publications

Shannon M Liudahl

1 joint publications

Cécile Alanio

1 joint publications

Byung S Park

1 joint publications

Thomas S Uldrick

1 joint publications

Elizabeth M Jaffee

Frequent Collaborators

2 joint publications

Elad Sharon

2 joint publications

Steven P Fling

1 joint publications

David L Bajor

1 joint publications

Daniel A Laheru

Top Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on : Oct 30, 2013

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on : Feb 14, 2025

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on : Jun 08, 2018

See more related videos

Top Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on : Oct 30, 2013

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on : Feb 14, 2025

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on : Jun 08, 2018

See more related videos